Background
==========

The onset of puberty is a complex and largely unknown process governed by interactions between genes and environment. The absence of signs of sexual maturation in boys (testicular enlargement ≥4 mL) by 14 years and in girls (breast bud development) by 13 years, which is 2--2.5 [s.d.]{.smallcaps} less than the mean population is usually referred to as delayed puberty ([@bib1]). Constitutional delay of growth and puberty (CDGP) accounts for the commonest cause of delayed puberty in both genders and it is twice as frequent in boys when compared to girls ([@bib2]). The other causes of delayed puberty include chronic illnesses, hypogonadotropic hypogonadism (HH) (Kallman's syndrome and hypopituitarism) and hypergonadotropic hypogonadism (Turner's syndrome, Klinefelter and gonadal toxicity).

Distinguishing CDGP from other causes of HH can be challenging. Careful clinical observation over time is essential as progressive pubertal development can happen in CDGP. The occurrence of progressive pubertal development by 18 years of age is the 'gold standard' for differentiating CDGP from HH ([@bib3]).

Pituitary adenomas are extremely rare in childhood and adolescence with a reported prevalence of 0.1 per million children ([@bib4]). They constitute less than 3% of supratentorial tumours and 2.3--6% of all sellar tumours treated surgically ([@bib5]). A retrospective review of adenomas diagnosed in adulthood suggested that symptoms often manifest during adolescence and that the prevalence of adenomas in children and adolescents may therefore be higher than reported ([@bib5]).

We report a teenage boy, presenting with delayed puberty, who was initially managed for constitutional pubertal delay but subsequent investigations led to the diagnosis of an extremely rare and clinically non-functioning (silent) Crooke's cell corticotroph adenoma. Crooke's cell adenoma, presenting as delayed puberty in children and adolescents, has not been reported in literature before.

Case presentation
=================

A 15-year-old boy (height: −1.6 SDS, weight −1.0 SDS, mid-parental height: 0.1 SDS) was referred for endocrinology consultation with concerns of delayed puberty. He had a Tanner pubertal staging of A1P2G1 and bilateral testicular volumes of 3 mL each. There was no history suggestive of chronic illnesses. His mother had attained menarche at 15 years of age and father was noted to be a late developer. There was no history of anosmia, headache and vomiting or visual disturbances. There were no features of hypothyroidism or cortisol excess.

Investigations
==============

The baseline laboratory investigations did not show any biochemical evidence of chronic illness. He had a bone age delay of 2 years. The thyroid function test, serum IGF1, prolactin, 09:00 h cortisol and ACTH were all within the normal limits ([Table 1](#tbl1){ref-type="table"}). The cortisol response (peak: 505 nmol/L at 60 min) to synacthen was adequate. The baseline LH was 0.8 IU/L, FSH was 1.4 IU/L and the morning testosterone was 0.8 nmol/L. The initial clinical impression was that of CDGP. The patient was closely monitored in the clinic. At 16 years, he still did not have any further progression towards puberty. An MRI scan of the brain showed a solid and cystic pituitary lesion (2 × 1.5 × 1.7 cm), which was slightly displacing the optic chiasma consistent with an adenoma ([Fig. 1A](#fig1){ref-type="fig"} and [B](#fig1){ref-type="fig"}). A detailed ophthalmology examination did not reveal any abnormality of vision. Genetic analysis of the *MEN1* and *AIP* did not reveal any pathogenic mutation. Figure 1MRI pituitary with contrast revealing a cystic lesion in the pituitary fossa (2 × 1.5 × 1.7 cm) slightly displacing the optic chiasma (red arrow). The pituitary gland itself or the posterior pituitary cannot be separated from the mass lesion (A, sagittal post-contrast, T1-weigthed image; B, coronal view showing mixed solid and cystic leison); postoperative MRI showing stable postsurgical changes noted within the sella with no evidence of recurrence of tumour (C, sagittal post-contrast, T1-weigthed image). Table 1Baseline endocrine investigations.**InvestigationsValues**Thyroid function test FT411.8 pmol/L TSH2.85 pmol/LProlactin100 µ/L (normal \<500)IGF143 nmol/L (normal: 24--102)Cortisol (09:00 h)300 nmol/LACTH (09:00 h)4 pmol/L (normal: 2--11)Synacthen test Peak cortisol response505 nmol/L at 60 minLH0.8 IU/LFSH1.4 IU/LTestosterone0.8 nmol/L

Treatment
=========

The pituitary lesion was removed by transphenoidal surgery and no evidence of calcification in the mass was noted. Post-operatively, the recovery was good without development of any new endocrine abnormality. The post-operative MRI, 6 months after the neurosurgery, was noted to be stable ([Fig. 1C](#fig1){ref-type="fig"}) and there was commencement of puberty, A2P3G2 with bilateral 5 mL testes.

Histopathology
==============

The tumour specimen contained normal adenohypophysis; fragments of a cyst walls lying adjacent to the normal anterior pituitary; and fragments of an adenoma with irregular, infiltrative margin into the adjacent gland. Immuno-histochemical stains were performed with antibodies directed against pituitary hormones, cytokeratin CAM5.2, Ki-67 and p53. The lesion was composed of acini, lobules, ribbons and trabeculae. The cytoplasm of neoplastic cells showed a perinuclear, pink, hyaline ring indicative of Crooke's hyaline changes ([Fig. 2A](#fig2){ref-type="fig"} and [B](#fig2){ref-type="fig"}). The adenoma cells were intensely and diffusely positive for ACTH ([Fig. 2C](#fig2){ref-type="fig"}). The immunostaining for cytokeratin CAM 5.2 highlighted perivascular cytokeratin deposits in the neoplastic cells that were typical of Crooke's hyaline changes, but not in the normal corticotrophes ([Fig. 2D](#fig2){ref-type="fig"}). Immunostaining for the other pituitary hormones were positive in the normal gland but were negative in the adenoma. About 2% of the neoplastic cells were positive for Ki-67; there was no overexpression of p53. The adenoma was adjacent to a cyst wall lined by single layer of flat and cuboidal cells on a thick basement membrane. No ciliated or mucinous cells were identified ([Fig. 3](#fig3){ref-type="fig"}). Figure 2Tissue fragments contain a pituitary adenoma and compressed normal adenohypophysis (A, haematoxylin--eosin-- ×10); neoplastic cells are uniform, show a peripheral rim of basophilic cytoplasm and perinuclear hyalinisation (B, haematoxylin--eosin -- ×40); the adenoma shows ubiquitous expression of ACTH (C, ACTH immunoperoxidase -- ×10); perinuclear hyaline changes consist of cytokeratin filaments (D, CAM5.2 immunoperoxidase -- ×40). Figure 3A cyst wall lined by flat and cuboidal epithelium on a thick basement membrane is adjacent to the normal adenohypophysis.

Outcome and follow-up
=====================

A further review after 6 months revealed a spontaneous pubertal progression (A2P4G4) with bilateral testicular volume of 8 mL. The plasma testosterone concentration was 10 nmol/L and GnRH test suggested a pubertal response (peak LH: 24.4 IU/L and FSH: 18 IU/L) suggesting a good recovery of hypothalamo--pituitary--gonadal axis post-surgery. There were no clinical signs of cortisol excess. An overnight dexamethasone suppression test (1 mg of oral dexamethasone at 23:00 h) supressed the 09:00 h cortisol to \<50 nmol/L ruling out biochemical hypercortisolism.

Discussion
==========

We report a teenager who presented with delayed puberty, which led to the initial clinical impression of constitutional delay: the most common cause of delayed puberty in boys. However further investigations established a diagnosis of pituitary adenoma, which was histologically proven to be a Crooke's cell adenoma (CCA).

Silent corticotroph pituitary adenomas (SCAs) are a rare form of pituitary adenomas that show positive staining for ACTH in immunohistochemical studies, but not associated with perioperative clinical or laboratory features of hypercortisolaemia ([@bib6]). SCAs are very rarely diagnosed in childhood and adolescence and they represent an uncommon cause of arrest in the pubertal development ([@bib7]). The most frequently reported presenting features of SCAs are tumour mass effects, including headaches, visual disturbance and hypopituitarism ([@bib8]). Our patient did not have features suggestive of raised intracranial pressure; however he had features of pituitary involvement in the form of hypogonadotropic hypogonadism.

Histologically, the lesion showed ACTH expression although the patient had no clinical evidence of cortisol excess. SCAs are usually biochemically silent but some SCAs have been reported to have elevated ACTH levels with normal cortisol levels ([@bib8]). The lack of signs and symptoms of hypercortisolim in patients with SCA may be related to dysregulated POMC processing leading to insufficient or bio-inactive ACTH molecules ([@bib9]). SCAs can be more aggressive than the other clinically non-functioning adenomas with a higher prevalence of cavernous sinus invasion and a higher rate of recurrences ([@bib10]).

Histologically, the tumour in our case had the features of CCA. CCA is an uncommon and under-investigated subtype of corticotroph adenoma accounting for less than 1% of the pituitary adenomas and 4% of the corticotropinomas ([@bib11]). CCA is reportedly an aggressive variant of corticotroph adenoma ([@bib11]). An extensive review of 80 cases published in the English literature showed that CCAs are more common in females (74.6%) and have a mean age occurrence of 42.4 years ([@bib12]). They usually present as macroadenomas (77.2%) frequently extending to the cavernous sinus or invading the sellar bone ([@bib13]). CCAs are rarely silent. Silent CCAs can occasionally change into a functioning adenoma, especially upon recurrence ([@bib13]). Diagnosis is only made on histopathological examination when Crooke's hyaline changes are present in more than 50% of the neoplastic cells.

The adenoma in our patient was also associated with a cyst consistent with Rathke's cleft cyst (RCC). The coexistence of adenoma and RCC is now known not to be as rare as thought previously ([@bib14], [@bib15]). Small, asymptomatic RCCs concomitant to adenoma are more frequent and are usually found as incidental post-mortem finding and the commonest association was with prolactinoma and the least frequent was ACTH-secreting adenomas ([@bib16]). Our patient had an initial clinical course suggestive of CDGP, but was subsequently identified to have a CCA that is currently biochemically and clinically silent.

Conclusion
==========

CCA is an uncommon form of corticotroph adenomas, which is usually associated with an aggressive clinical course. Rarely, as in our case, CCAs can be clinically silent but require careful monitoring to identify the possible change to Cushing's disease, and post-operative recurrences. The case also highlights the well-established fact that systematic and careful review is important while assessing boys with delayed puberty, as CDGP should be a diagnosis of exclusion.
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